Document is current
Any future updates will be listed below
-
Authors
El Chaer, Firas
Bewersdorf, Jan P. https://orcid.org/0000-0003-3352-0902
Stahl, Maximilian
Zeidan, Amer M.
- License Information
-
More Information
Article History
Accepted: 29 October 2025
First Online: 5 December 2025
Competing interests
: F.E.C. has acted as a consultant and/or adviser of AbbVie, Amgen, the Association of Community Cancer Centers, Bristol Myers Squibb (BMS), CTI BioPharma, Daiichi Sankyo, DAVA Oncology, Geron, MorphoSys, Novartis, PharmaEssentia, Sobi, Sumitomo Pharma Oncology, Syndax and Taiho Oncology; he also received a travel grant from DAVA Oncology. M.S. has acted as a consultant and/or adviser of Boston Consulting, BMS, Dedham group, GSK, GLG Insights, Kymera, Kura, Novartis, Rigel, Sierra Oncology, Sobi and Syndax; has participated in CME activity for Clinical Care Options, Curis Oncology, Haymarket Media and Novartis; and is a member of the Medical Safety Monitoring Board for Keros Pharmaceuticals. A.M.Z. has participated in advisory boards, consulted for, participated in clinical trial committees for and/or received honoraria from AbbVie, Agios, Akesobio, Amgen, Astellas, Beigene, BioCryst, Boehringer-Ingelheim, Celgene/BMS, Chiesi/Cornerstone Biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, Faron, Fibrogen, Genentech, Geron, Glycomimetics, Gilead, GSK, Janssen, Jasper, Karyopharm, Keros, Kura, Kyowa Kirin, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Syndax, Syros, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis. J.P.B. declares no competing interests.
